Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / XERS - Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect

XERS - Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect

Xeris Pharmaceuticals Inc.

--News Direct--

Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development.

Edick says the agreement will see Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron.

Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization.

Contact Details

Proactive Investors

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/xeris-biopharma-enters-research-collaboration-with-regeneron-pharmaceuticals-to-advance-xeriject-468188646

Stock Information
Company Name: Xeris Pharmaceuticals Inc.
Stock Symbol: XERS
Market: NASDAQ
Menu
XERS XERS Quote XERS Short XERS News XERS Articles XERS Message Board
Get XERS Alerts

News, Short Squeeze, Breakout and More Instantly...